Alfabet PF Eye Drop
Manufacturer
His Eyeness Ophthalmics Pvt Ltd
Salt Composition
Timolol (0.5% w/v) + Brimonidine (0.2% w/v)
Key Information
Short Description
Alfabet PF Eye Drop is a prescription medicine used for the treatment of pressure in the eyes (ocular hypertension) and glaucoma.
Dosage Form
Eye Drop
Introduction
Alfabet PF Eye Drop is a combination of two medicines that lowers high pressure in the eye and reduces the risk of vision loss. It works by decreasing the pressure of fluid in the eye (aqueous humor), which helps in lowering the increased eye pressure.
Directions for Use
This medicine is for external use only. Use it in the dose and duration as advised by your doctor. Check the label for directions before use. Hold the dropper close to the eye without touching it. Gently squeeze the dropper and place the medicine inside the lower eyelid. Wipe off the extra liquid.
Safety Information
Side Effects
No common side effects listed
Alcohol Warning
No interaction found/established
Breastfeeding Warning
Information regarding the use of Alfabet PF Eye Drop during breastfeeding is not available. Please consult your doctor.
Pregnancy Warning
Information regarding the use of Alfabet PF Eye Drop during pregnancy is not available. Please consult your doctor.
How it works
Alfabet PF Eye Drop is a combination of two medicines: Timolol and Brimonidine. Timolol is a beta blocker while Brimonidine is a sympathomimetic. They work by decreasing the production of aqueous humor (fluid in the eye) thereby lowering the increased eye pressure.
Quick Tips
Alfabet PF Eye Drop is a combination of two medicines that lowers high pressure in the eye and reduces the risk of vision loss Apply pressure on the corner of the eye (close to the nose) for about 1 minute immediately after instilling the drop Do not touch the tip of the dropper to any surface or to your eye to avoid contaminating the eye drops Wait for at least 5-10 minutes before delivering the next medication in the same eye to avoid dilution It may cause short term blurring of vision when first used. Use caution before driving or using machines It may cause temporary burning or itching sensation in the eye. Inform your doctor if this does not go away Make sure to use within 4 weeks of opening the bottle
Related Medicines
Betabrim Eye Drop
Albrim T Eye Drop
Armbri-T Eye Drop
Arobrim T Eye Drop
Cibrim-T Eye Drop BAK Free
Presbrim T Eye Drop
Duobrim T Eye Drop
Ruflom T Eye Drop
Visobrim-T Eye Drop
BRM T Eye Drop
Frequently asked questions
How to use Alfabet PF Eye Drop?
To apply Alfabet PF Eye Drop, wash your hands thoroughly before handling the bottle. Do not touch the tip of the dropper. If you wear contact lenses, remove them before using Alfabet PF Eye Drop. Tilt your head back, look up, and gently pull down your lower eyelid to create a pouch for the drops. Then, carefully place a few drops into the pouch.
Can Alfabet PF Eye Drop be stopped when symptoms are relieved?
No, Alfabet PF Eye Drop should continue as directed by your healthcare provider. If you experience any difficulties or have concerns about using this medication, consult your doctor for further evaluation.
Can the use of Alfabet PF Eye Drop cause blurry vision?
Temporary blurred vision is a potential side effect of Alfabet PF Eye Drop. Avoid driving or operating machinery until your vision fully recovers.
What are the instructions for the storage and disposal of Alfabet PF Eye Drop?
Keep Alfabet PF Eye Drop in its original container, tightly closed at all times. Store it according to the instructions provided on the packaging or label. Dispose of unused medication. Make sure it is not accessible to children, pets or others.
What are the contraindications associated with the use of Alfabet PF Eye Drop?
Alfabet PF Eye Drop should be avoided by patients who have hypersensitivity to Timolol, Brimonidine, or any of its components. Additionally, this medication is not recommended for individuals with airway disease, lung disease, or heart disease. This medication is also contraindicated in children under 2 years old.
